A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis [PDF]
New England Journal of Medicine, 2012 Ruben Mesa, Jason Gotlib, Vikas Gupta
exaly +5 more sources
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]
Cancer Medicine, 2019 Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF).
Novella Pugliese +14 more
doaj +2 more sources
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial [PDF]
Journal of Hematology & Oncology, 2017 Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
Srdan Verstovsek +21 more
doaj +3 more sources
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I [PDF]
Haematologica, 2015 In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo ...
Srdan Verstovsek +21 more
doaj +3 more sources
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis [PDF]
Blood Advances: Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic response. ADORE was
David M. Ross +22 more
doaj +2 more sources
Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review [PDF]
Frontiers in OncologyMyelofibrosis (MF) is a philadelphia chromosome-negative chronic myeloprolifera- tive neoplasm.It has a worse prognosis than polycythemia vera and essential thrombocy- themia.At present,both Chinese and foreign guidelines recommend ruxolitinib as first ...
Xiaohong Liu, Xiujuan Zhang, Hongxia Shi
doaj +2 more sources
Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing [PDF]
, 2013 Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and ...
Jorge Cortes, Ruben A Mesa
core +3 more sources
Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3 [PDF]
Blood Advances: Azole antifungal agents, commonly used for preventing invasive fungal infections in graft-versus-host disease (GVHD), are known to affect ruxolitinib metabolism.
Zahra Mahmoudjafari +6 more
doaj +2 more sources
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
New England Journal of Medicine, 2015 Alessandro Maria Vannucchi +2 more
exaly +2 more sources
Analysis of adverse events with ruxolitinib using real-world datasets and drug-interaction networks [PDF]
SAGE Open MedicineObjectives: Ruxolitinib is used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease following allogeneic stem cell transplantation.
Hideyuki Tanaka +15 more
doaj +2 more sources